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Background: Neoadjuvant radiotherapy (NRT) is an effective strategy to treat soft tissue sarcomas (STS). However,
the role of neoadjuvant chemoradiotherapy (NCRT) remains to be determined.
Methods: From May 1999 to July 2010, 112 patients with localized STS of the extremity and trunk who were
treated with NRT or NCRT followed by surgery were retrospectively reviewed. Clinical outcomes including overall
survival (OS), disease-free survival (DFS), and distant metastasis free survival (DMFS) were calculated using Kaplan-
Meier survival analyses. Prognostic variables were determined by univariate (UVA) and multivariate analyses (MVA).
Results: Median follow-up was 37 months. Median RT dose was 50 Gy. Forty-nine patients received NCRT. Overall
limb-preservation rate was 99% and local control was 97%. The estimated 3-year OS, DFS, and DMFS were 86%,
68%, and 72%, respectively. Age was the only variable to predict for OS, DFS and DMFS on UVA. Age ≥ 70
predicted for poor OS, stage III disease predicted for poor DFS and DMFS, and the addition of chemotherapy
predicted for improved DMFS on MVA.
Conclusions: Excellent rates of local control and limb-preservation were observed in patients with primary STS
treated with neoadjuvant therapy followed by surgery. Neoadjuvant sequential chemotherapy followed by
radiotherapy may be considered for young patients with stage III STS.
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The management of soft tissue sarcomas (STS) of extrem-
ity and trunk has evolved in the past two decades. Limb-
salvage surgery combined with either pre-operative or
post-operative radiotherapy has now become the standard
of care over amputation [1-3]. Although there is no defini-
tive evidence to support a survival benefit of neoadjuvant
radiotherapy over adjuvant radiotherapy, results from a re-
cent Phase III study demonstrate a significant advantage
of neoadjuvant radiotherapy in the reduction of late radi-
ation morbidities, such as fibrosis, joint stiffness and* Correspondence: dwang@mcw.edu
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reproduction in any medium, provided the oredema [4]. Reduction of late radiation morbidities is im-
portant in patient’s quality of life, as these morbidities are
most likely irreversible. Additional advantages of neo-
adjuvant radiotherapy are a decrease in target volume, ra-
diation dose and tumor seeding during sarcoma resection,
as well as an occasional reduction in tumor mass that
might facilitate complete resection [5-7].
Neoadjuvant chemoradiotherapy has been utilized in the
management of high-risk STS of extremities [8-11]. For
instance, neoadjuvant chemotherapy (MAID regimen) in-
terdigitated with neoadjuvant radiotherapy (44 Gy in 22
fractions) has been shown to decrease the rate of distant
metastasis (DM) and to increase disease free survival
(DFS) and overall survival (OS) in patients with STS of the
extremity and trunk with ≥ 8 cm tumors compared withd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was a single-arm phase II trial that enrolled 64 patients
with intermediate-to-high grade, ≥ 8 cm STS of the extrem-
ity or torso with expected margin-negative (R0) resection.
The 3-year loco-regional failure was 18% if amputation was
considered a failure and 10% if not. Estimated 5-year
rates of DFS, distant metastasis-free survival (DMFS),
and OS were 56.1%, 64.1%, and 71.2%, respectively. How-
ever, significant toxicities associated with this aggressive
neoadjuvant chemoradiotherapy regimen have precluded
widespread use of this regimen [9].
Neoadjuvant sequential chemoradiotherapy has been
known to be less toxic than neoadjuvant concurrent/in-
terdigitated chemoradiotherapy and is commonly used
to treat high-risk STS at many institutions. However, it
remains to be determined whether this approach pro-
vides a survival benefit in patients with STS of the ex-
tremity and trunk. In this study, we analyzed a cohort of
patients with primary STS of the extremity and trunk
who received neoadjuvant radiotherapy with or without
sequential neoadjuvant chemotherapy at our institution.
The aim of this retrospective study was to determine the
clinical and pathologic variables that predict for im-
proved OS, DFS, and DMFS in patients with STS treated
with this regimen.
Materials and methods
This research was reviewed and approved by the Institu-
tional Review Board (IRB) and all investigators completed
training in both human research and patient privacy.
Patients
All patients with primary STS of the upper and lower ex-
tremities and trunk who received radiation with or without
chemotherapy followed by surgical resection between May
1999 and October 2010 were reviewed. Exclusion criteria
included metastatic disease on initial presentation, age < 18
years old, STS of locations other than the extremity or
trunk, recurrent sarcomas at first presentation, and his-
topathologic types demonstrating rhabdomyosarcoma,
extraosseous primitive neuroectodermal tumor, Ewing
sarcoma, osteosarcoma, Kaposi’s sarcoma, angiosarcoma,
aggressive fibromatosis, or dermatofibrosarcoma pro-
tuberans. Patients who did not have complete medical re-
cords including treatment information and a pathology
report, and follow-up of less than 6 months were also
excluded. Patients were staged according to the 2009
American Joint Committee on Cancer (AJCC) system
seventh edition.
Statistical analysis
The sample size for this analysis was 112 patients. Poten-
tial prognostic variables assessed were location, grade,
size, depth, age, percent necrosis on surgical specimens,whether neoadjuvant chemotherapy was administered, and
the number of chemotherapy cycles. The 2, 3 and 5-year
OS, DFS, and DMFS rates were estimated using the
Kaplan-Meier estimate of the survival function. The log-
rank test was used to compare two survival curves. Univa-
riate and multivariate analyses were performed to deter-
mine prognostic variables in correlation with the above
survivals. For multivariate analysis, the Cox proportional
hazards model was used. All potential risk factors were first
tested for affirmation of the potential hazards assumptions.
No factors were found to violate the proportional hazards
assumption. A step-wise model building procedure was
then performed to develop multivariate models for each
outcome. For all analyses, the type I error was maintained
at 0.05 and all tests were two-sided. All statistical analyses
were performed in SAS, ver. 9.1 (Cary, NC).
Results
Patient characteristics
There were 112 patients with stage I-III STS of extrem-
ity and trunk that were included in this analysis. Median
age was 54.5 years old, with a range between 18 to 92
years. Patient characteristics are listed in Table 1.
The most common histology was malignant fibrous
histiocytoma (30.3%). Other histologies included liposar-
coma (23.2%), myxofibrosarcoma (14.3%), leiomyosarcoma
(8.9%), synovial sarcoma (8.0%), extraskeletal myxoid
chondosarcoma (2.7%), malignant peripheral nerve sheath
tumor (3.6%), solitary fibrous tumor (3.6%), spindle cell
sarcoma, NOS (1.8%), epitheliod sarcoma (1.8%), and fibro-
sarcoma (1.8%). Nineteen patients (17%) had low grade,
6 (5%) had intermediate grade, and 87 (78%) had high
grade disease.
All patients underwent external beam radiotherapy
followed by limb-sparing, wide-local excision. The median
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three-dimensional radiotherapy or intensity modulated ra-
diation treatment. Of the patients with accessible radiation
records, a three-dimensional technique was used in 79.4%
and IMRT was used in 20.6% of patients. Surgical resection
was performed 4–8 weeks after completion of radiation
treatment. Negative margins, which are defined as tumor
on ink, were achieved in 92% of all cases upon wide local
excision. The limb-preservation rate was 99%. One patient
underwent an amputation for a failed infected reconstruc-
tion with vascular flap. Immediate flap reconstructions were
performed in 53 (47.5%) of patients.
Forty-nine patients (40%) received neoadjuvant chemo-
therapy prior to the initiation of radiation. All chemother-
apy was doxorubicin and ifosfamide-based regimens
(Table 2). Twenty-eight patients (57%) received 3 or more
cycles of chemotherapy, 20 of these patients received less
than 3 cycles of chemotherapy, and 63 (56%) patients re-
ceived no chemotherapy. The number of cycles of chemo-
therapy was unknown in one patient. Neoadjuvant
chemotherapy was often given to young patients (<70
years old) with clinical stage III (large, deep, intermediate-
to-high grade) STS. Neoadjuvant chemotherapy was given
to 4 out of 48 (8.3%) patients ≥70 years old compared to
27 out of 64 patients (42.2%) who were <70 years old and
did not receive chemotherapy (p<0.0001).
Adjuvant chemotherapy was also delivered in 14 pa-
tients who received neoadjuvant chemotherapy. Twelve
patients received a doxorubicin-ifosfamide based regi-
men, one patient received an epirubicin-ifosfamide based
regimen, and one patient received adjuvant chemother-
apy at an outside clinic, but the regimen was not avail-
able for review. One patient received five cycles of
adjuvant chemotherapy, 5 patients received two cycles, 2
patients received three cycles, and the remaining 6 re-
ceived an undetermined number of cycles.Table 2 Demographics of patients receiving neoadjuvant
chemotherapy
Variable NRT NCRT
Age ≤70 39 (45%) 48 (55%)
>70 21 (84%) 4 (16%)
Stage I 18 (9.5%) 1 (5%)
II 10 (62.5%) 6 (37.5%)
III 33 (43%) 44 (57%)
Grade Low 18 (95%) 1 (5%)
Intermediate 4 (67%) 2 (33%)
High 38 (44%) 49 (56%)
Size ≤5 cm 3 (30%) 7 (70%)
>5 cm 49 (48%) 53 (52%)
NRT: neoadjuvant radiotherapy. NCRT: neoadjuvant chemoradiotherapy.Pathologic outcomes
Percent necrosis was documented in 102 of the 112 pa-
tients in our database. The original pathology reports
were centrally reviewed by our sarcoma pathologist
(EZ), who was blind to clinical outcomes. Ten patients
had 100% necrosis of their tumor after neoadjuvant
treatment, 14 patients had ≥99% necrosis, 23 patients
had ≥95% necrosis, 20 patients had 80-94% necrosis, 20
patients had 50-79% necrosis, and 39 patients had less
than 50% necrosis of their tumor.
Clinical outcomes
Median follow-up was 3.1 years. Eight patients were lost
to follow-up. The local control rate for the entire study
population was 97% at this follow-up. Two of the 3 pa-
tients that failed locally did so after the development of
distant metastasis. The distant metastasis rate for the
study group was 27.6%. The median time to death was
23.5 months. The median time to disease progression
was 16.3 months. The median time to distant metastasis
was 15.6 months.
The median OS, DFS and DMFS was > 124 months
(Figure 1A, 1B, and 1C), with a 3-year OS of 85.5%, 3-
year DFS of 68.3%, and 3-year DMFS of 71.7%.
There was no significant difference in the OS (p=0.42),
DFS (p=0.29), and DMFS (p=0.12) between T1 (tumor
≤5 cm) and T2 (tumor >5 cm) STS. There was no sig-
nificant difference in OS (p=0.73), DFS (p=0.41), and
DMFS (p=0.48) between deep and superficial sarcomas.
There 3-year OS for low, intermediate and high grade
disease was 93.7%, 83.3% and 84.6%, respectively (p=0.5).
The 3-year DFS for low, intermediate and high grade
disease was 83.1%, 76.2%, and 64.9%, respectively
(p=0.2). The 3-year DMFS was 82.6%, 71% and 69%, re-
spectively (p=0.2).
Necrosis assessed on pathology from the surgical spe-
cimen was grouped according to the degree of necrosis
after the central pathology review. There was no signifi-
cant difference in OS (p=0.4), DFS (p=0.37), and DMFS
(p=0.71) in patients who had ≥95% vs. ≥80%-94% vs.
≥50%-79% vs. <50% necrosis.
On univariate analysis, age <70 predicted for OS
(p=0.019), DFS (p=0.037), and DMFS (p=0.021). Stage also
predicted for DMFS on UVA (p=0.017). No other variable
was significant for OS, DFS or DMFS. On multivariate
analysis, age ≥70 was significant for poor OS (p=0.026),
stage III disease was significant for poor DFS (p=0.041)
and DMFS (p=0.004), and the addition of neoadjuvant
chemotherapy prior to preoperative radiotherapy was sig-
nificant for improved DMFS (p=0.041) (Figure 2).
Discussion
High local control rates have been demonstrated using
multimodality therapy for STS. Yang et al., showed that the
Figure 1 Overall survival (A), disease-free survival (B), distant metastasis free survival (C) of the entire group.
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proved local control rates in both high and low grade tu-
mors [12]. Several other studies have demonstrated high
local control rates of approximately 90% at 5 years with
preoperative radiotherapy with or without chemotherapy
[4,13-16] (Table 3). Brant, et al., demonstrated a 91% local
control rate in 58 patients with STS of the extremity or
trunk who were treated with preoperative radiation alone
followed by surgical resection. The University of Florida
series was recently updated with an overall local control
rate of 94%. Similarly, Barkley, et al. also had high rates of
local control [13,14,17]. Studies that have compared pre-
operative radiation to post-operative radiation have also
shown equivalent outcomes for local control [4,15,16].
Similarly, this study demonstrates a high local control
rate of 97% at a median follow-up of 3.1 years for those
treated with preoperative radiation therapy followed by
limb-sparing surgery. This suggests that neoadjuvantTim
Figure 2 Distant metastasis free survival (DMFS) of patients with neoadradiotherapy combined with surgical resection does not
compromise local control in STS of the extremity and trunk.
Neoadjuvant chemotherapy is often preferred over ad-
juvant chemotherapy, although there is no level one evi-
dence to support a survival advantage with the use of
neoadjuvant chemotherapy in patients with STS. The
Sarcoma Meta-analysis of STS patients enrolled into 14
randomized trials revealed that adjuvant chemotherapy
was found to improve local recurrence-free survival by
6%, distant and overall recurrence-free survival by 10%
[18]. However, proponents for neoadjuvant chemotherapy
argue that oncologists are able to monitor response and
alter or terminate therapy in patients who do not appear
to be deriving any benefit. Gortzac, et. al reported results
of a phase II study that examined patients with high-risk
sarcomas who were randomized to surgery alone vs. three
cycles of doxorubicin and ifosfamide prior to surgery.
After a median follow-up of 7.3 years, the addition ofNo Neoadjuvant Chemotherapy
Neoadjuvant Chemotherapy
e (months)
juvant chemotherapy versus without neoadjuvant chemotherapy.
Table 3 Local control with neoadjuvant radiotherapy for primary soft tissue sarcomas of extremity and/or trunk
Study Institution Number of pre-op patients & follow-up Chemotherapy included Median RT dose (Gy) Local control
Dagan , et al. U of Florida 317 Yes 50.4 94%
4.7 y
O'Sullivan, et al. NCI 93 No 50 93%
3.3 y
Sampath, et al. Utah 293 Yes 50.4 93%
5.25 y
Zagars, et al. MDACC 271 Yes 50 87%
6 y
Bedi, et al. MCW 112 Yes 50 97%
3.1 y
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[19]. Authors concluded that this study did not have
enough power to address survival. Therefore, neoadjuvant
chemotherapy alone should not be routinely recommended
to all patients with STS.
The results from this study show that the use of
neoadjuvant sequential chemotherapy was associated
with a higher DMFS in patients <70 years old with clin-
ical stage III STS of the extremity and trunk. This is si-
milar to the results of other studies compared with
historical controls [8,9]. The mechanism of biological
synergy from neoadjuvant sequential chemoradiotherapy
remains unknown. Considering the rarity of STS and un-
certain response of some STS to neoadjuvant chemother-
apy, the authors would therefore recommend neoadjuvant
sequential chemoradiotherapy be considered in treating
patients <70 years old with stage III STS in centers with
considerable multidisciplinary expertise and experience in
managing these patients and where such an approach can
be discussed for appropriate patients in the setting of a
multidisciplinary sarcoma tumor board. As such, close
monitoring of these patients are essential during the
course of neoadjuvant chemotherapy. At our institution,
patients <70 years old with stage III STS of the extremity
and trunk are jointly evaluated by all disciplines.
The decision to administer neoadjuvant chemotherapy
prior to radiation is dependent on several factors. Grade,
tumor size, and histology all are taken into account, as
well as patient factors such as performance status, cardio-
vascular and renal functioning and patient preference.
Typically, chemotherapy is recommended in high grade
STS with certain histologies that are ≥5cm in size or deep
tumors. These histologies include synovial sarcoma,
myxoid liposarcoma, dedifferentiated liposarcoma, poorly
differentiated STS, and leiomyosarcoma. These patients
are also offered neoadjuvant sequential adriamycin-
ifosfamide chemotherapy for three cycles. These patients
might receive immediate preoperative radiotherapy due to
significant tumor pain or growth after 1 or 2 cycles ofchemotherapy. All patients will have a CT scan of the
chest and an MRI of the primary sarcoma after 2 cycles of
chemotherapy. Those patients whose tumors are stable or
shrink would proceed with the third cycle of neoadjuvant
chemotherapy prior to preoperative radiotherapy. All of
the above scenarios should be extensively discussed with
these patients prior to initiating treatment.
Prognostic variables have been investigated in many
retrospective studies [20-29]. Stevanovski, et al. have dem-
onstrated that stage is prognostic in OS; other studies
show that grade, size, and depth of tumor all are prognos-
tic in terms of OS, disease-specific survival, and DMFS
[19-25]. In this study, the UVA showed age ≥ 70 was the
only variable that predicted for OS, DFS, and DMFS, and
stage III disease predicted for poor DMFS. On MVA, age
≥70 was significant for poor OS, stage III disease was sig-
nificant for poor DFS and DMFS, and the addition of
neoadjuvant chemotherapy prior to preoperative radio-
therapy was significant for improved DMFS.
Age at diagnosis has been demonstrated to be a prog-
nostic indicator in several other studies [21,27-29]. Both
Pisters, et al. and Gronchi et al., showed decreased local
control rates in patients with STS [21,27]. A study done
by Collin et al., revealed that survival was also impacted in
patients who were > 53 years old at diagnosis, and Kaytan,
et al. also showed poorer survival in patients > 50 years of
age [28,29]. These studies corroborate our finding that ad-
vanced age at diagnosis may portend to poorer outcomes.
Furthermore, a 12-year sarcoma-specific death nomogram
has been created by Kattan and colleagues, which uses age
as one of the nomogram predictor variables [30].
Treatment-induced tumor necrosis due to radiation with
or without chemotherapy has been sparsely reported. Eliber,
et al., showed improved 5-year survival rates of 80% vs.
62% in tumors with near-complete necrosis [11]. Similarly,
MacDermed, et al. demonstrated a 5-year freedom-from
-distant metastasis rate of 84.6% in patients who had a
high rate of necrosis after treatment (≥90%) vs 19.9% in
tumors that had less extensive necrosis [31]. However, a
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that a near complete necrosis after neoadjuvant interdigi-
tated chemoradiotherapy did not predict for any survival
outcomes [8]. Similarly, results of this study showed the
percent of necrosis after preoperative radiotherapy with or
without chemotherapy did not impact OS, DFS, or DMFS.
The reasons for the differences from our study are unclear
and could be secondary to tissue sample selection that is
not able to be examined in a retrospective study. There
are also several issues about documenting percent of ne-
crosis after neoadjuvant treatment for STS. First, there are
no methods to differentiate between treatment-induced
necrosis and tumor-related necrosis either through im-
aging studies or pathology examination. Second, the pre-
and post-treatment percent of necrosis were not able to be
compared in our study and other studies [11,31]. Third,
percent of necrosis was not uniformly evaluated in above
studies due to the large size of STS, as there was a tech-
nical challenge to evaluate entire specimen of large STS.
Finally, different from many other types of human malig-
nancy, high grade and large size are often associated with
a significant increase in STS necrosis at initial diagnosis.
This observation is confirmed in our study.
Limitations of this study include the inherent biases of
a retrospective review and the relatively small sample
size. Moreover, there were a heterogeneous group of tu-
mors analyzed.Conclusions
Excellent rates of local control and limb-preservation
were observed in patients with primary STS of the ex-
tremity and trunk treated with neoadjuvant radiation or
neoadjuvant sequential chemoradiation followed by sur-
gery. Age ≥70 years old was the only variable alone
found to be prognostic for poor OS, DFS, and DMFS
and stage III disease predicted for poor DMFS on UVA.
Results of the MVA suggest that neoadjuvant sequential
chemotherapy followed by radiation may be considered
for young patients (<70 years old) with stage III STS of
the extremity and trunk.Competing interest
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